Tabara H, Kinugasa S, Tachibana M, Abe S, Yoshimura H, Suzuki K, Monden N, Nakamura T
Second Dept. of Surgery, Shimane Medical University.
Gan To Kagaku Ryoho. 1995 Sep;22(11):1473-6.
Plachitin is a chemical compound of cis-diammine-dichloroplatinum (CDDP) and chitin. Pharmacokinetics and adverse effects of Plachitin for intraperitoneal chemotherapy (IP) were studied in 11 patients who suffered from non-curative gastrointestinal cancers in comparison with 4 patients who underwent IP of CDDP. Five patients were given 300 mg (100 mg as CDDP) of Plachitin which was cotton type on the residual cancer mass (Group A). Six patients were given IP 300 mg of Plachitin particles (Group B). As the control group, 4 patients were given IP 100 mg of CDDP (Group C). The platinum concentrations of serum, urine and intraperitoneal discharge were observed during 3-4 weeks after the treatments and calculated as the CDDP concentration. The serum CDDP levels were below 0.1 micrograms/ml for 4 weeks in Group A and B. In Group A, urine concentrations of CDDP were significantly lower than in Group B and C at 3 and 5 days after the treatment statistically (p > 0.05). But at 14 days after treatment, the urine concentration of CDDP in Group A was higher than in Group C. In Group A and B, the CDDP concentrations of intraabdominal discharge was lower than in Group C statistically (p > 0.05). Nausea was observed only in one patient of Group B and other adverse effects which contained renal sufficiency were not recognized in the three groups. Thus, Plachitin was considered an effective and safe agent for intraperitoneal chemotherapy.
普拉奇汀是顺二氯二氨铂（CDDP）与几丁质的化合物。对11例非根治性胃肠道癌患者进行了普拉奇汀腹腔化疗（IP）的药代动力学和不良反应研究，并与4例接受CDDP腹腔化疗的患者进行比较。5例患者在残留癌灶上给予300mg（相当于100mg CDDP）棉型普拉奇汀（A组）。6例患者腹腔注射300mg普拉奇汀颗粒（B组）。作为对照组，4例患者腹腔注射100mg CDDP（C组）。在治疗后3至4周观察血清、尿液和腹腔引流液中的铂浓度，并以CDDP浓度计算。A组和B组血清CDDP水平在4周内低于0.1μg/ml。在A组中，治疗后第3天和第5天，CDDP的尿液浓度显著低于B组和C组（p>0.05）。但在治疗后14天，A组CDDP的尿液浓度高于C组。A组和B组腹腔引流液中CDDP浓度低于C组（p>0.05）。仅B组1例患者出现恶心，三组均未发现包括肾功能不全在内的其他不良反应。因此，普拉奇汀被认为是一种有效且安全的腹腔化疗药物。
